CrystalGenomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 14, 2022 at 03:54 am EST
Share
CrystalGenomics, Inc. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was KRW 61.95 million compared to KRW 113.6 million a year ago. Net loss was KRW 3,963.09 million compared to KRW 771.14 million a year ago. Basic loss per share from continuing operations was KRW 63. Diluted loss per share from continuing operations was KRW 63.
For the nine months, sales was KRW 342.12 million compared to KRW 295.71 million a year ago. Net loss was KRW 12,801.37 million compared to net income of KRW 363.15 million a year ago.
CG Invites Co Ltd is a Korea-based company principally engaged in the development and manufacturing of pharmaceuticals. The Company operates its business through three segments. The Pharmaceutical Research and Development segment is engaged in the research, development and sale of new drugs such as anti-inflammatory painkillers, anticancer drugs, anti-infectives and others. It is also engaged in the real estate rental business. The Pharmaceutical Manufacturing segment is engaged in the manufacture, retail and wholesale of finished drug products. The Other segment is engaged in the manufacture and sale of hot packs and other household items.